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ABSTRACT Reactivation of human cytomegalovirus (HCMV) latent infection from
early myeloid lineage cells constitutes a threat to immunocompromised or immune-
suppressed individuals. Consequently, understanding the control of latency and re-
activation to allow targeting and killing of latently infected cells could have far-
reaching clinical beneﬁts. US28 is one of the few viral genes that is expressed during
latency and encodes a cell surface G protein-coupled receptor (GPCR), which, during
lytic infection, is a constitutive cell-signaling activator. Here we now show that in
monocytes, which are recognized sites of HCMV latency in vivo, US28 attenuates
multiple cell signaling pathways, including mitogen-activated protein (MAP) kinase
and NF-B, and that this is required to establish a latent infection; viruses deleted
for US28 initiate a lytic infection in infected monocytes. We also show that these
monocytes then become potent targets for the HCMV-speciﬁc host immune re-
sponse and that latently infected cells treated with an inverse agonist of US28 also
reactivate lytic infection and similarly become immune targets. Consequently, we
suggest that the use of inhibitors of US28 could be a novel immunotherapeutic
strategy to reactivate the latent viral reservoir, allowing it to be targeted by preexist-
ing HCMV-speciﬁc T cells.
IMPORTANCE Human cytomegalovirus (HCMV) is a betaherpesvirus and a leading
cause of morbidity and mortality among immunosuppressed individuals. HCMV can
establish latent infection, where the viral genome is maintained in an infected cell,
without production of infectious virus. A number of genes, including US28, are ex-
pressed by HCMV during latent infection. US28 has been shown to activate many
cellular signaling pathways during lytic infection, promoting lytic gene expression
and virus production. As such, the role of US28 remains unclear and seems at odds
with latency. Here, we show that US28 has the opposite phenotype in cells that sup-
port latent infection—it attenuates cellular signaling, thereby maintaining latency.
Inhibition of US28 with a small-molecule inhibitor causes HCMV latent infection to
reactivate, allowing latently infected cells to be detected and killed by the immune
system. This approach could be used to treat latent HCMV to clear it from human
transplants.
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Human cytomegalovirus (HCMV) is a betaherpesvirus which has characteristic lyticand latent stages as part of its lifecycle (1). It is a widespread pathogen, estab-
lishing lifelong infection in 50% to 90% of the population (2). Due to robust host T cell
and antibody immune responses, primary infection with HCMV is rarely symptomatic in
healthy individuals. Despite this, HCMV infection is never cleared after primary infection
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but persists for the lifetime of the host; this is due, at least in part, to the ability of the
virus to establish a latent infection which helps support immune evasion (3). Although
primary infection, as well as sporadic reactivation from latency, is asymptomatic in
healthy individuals, it can be a severe clinical threat in immunocompromised individ-
uals, such as transplant recipients and patients with AIDS (4).
Although many cell types become lytically infected upon primary HCMV infection
(5), only cells of the early myeloid lineage have been shown to carry latent virus in vivo.
These include CD34 progenitor cells as well as their derivative CD14 monocytes (4).
In these cells, the viral genome is maintained with a limited latency-associated tran-
scription program which does not support the production of infectious virus. Differen-
tiation of these latently infected early myeloid lineage cells to macrophages or dendritic
cells (DCs) triggers the lytic transcription program and full virus reactivation (6–12). It
is now relatively well established that the differentiation-dependent reactivation of
HCMV in the myeloid lineage is associated with changes in posttranslational modiﬁ-
cations of histones around the major HCMV lytic promoter, namely, the major imme-
diate early promoter (MIEP). These changes drive expression of the major lytic IE72 and
IE86 viral gene products, thereby initiating the lytic transcription program and the
production of infectious virions (7, 9, 12–17). While the exact signals associated with
myeloid differentiation which induce HCMV reactivation are far from clear, it is becom-
ing apparent that orchestrated effects of both cellular and viral factors are involved in
this derepression of the MIEP and induction of the lytic transcription program (15,
18–22) and that these effects are likely to involve extracellular signal-regulated kinase–
mitogen-activated protein kinase (ERK-MAP kinase) signaling (23). Consequently, these
pathways, which are activated during myeloid cell differentiation and maturation, are
likely to play a prominent role in the differentiation-dependent activation of the MIEP
(18–20, 24–28).
Besides repression of the MIEP and expression of speciﬁc latency-associated viral
gene products (29–36), latent HCMV carriage has been shown to cause changes in the
cellular microRNAome (37, 38), the cellular secretome (39), and cell surface protein
expression (40); all of these are likely to be mediated by expression of latency-
associated genes (41). One of these, US28, is a G protein-coupled receptor (GPCR) and
chemokine receptor (CCR) homologue whose expression has been detected in both
natural and experimental models of HCMV latency (30, 31, 35, 42). US28 is one of four
HCMV-encoded CCR homologues and is the only one to be expressed during both lytic
and latent infection; the other CCR homologues, UL33, UL78, and US27, are expressed
only during lytic infection (43–45). Supporting this assertion, deletion of the US27,
UL33, and UL78 genes does not affect the establishment of HCMV latency, whereas
deletion of the US28 gene has profound effects on latent infection in CD34 progenitor
cells and leads to lytic infection in these undifferentiated myeloid cells, due to a lack of
MIEP repression (21).
US28 is the best characterized of the CCR homologues encoded by HCMV, and its
structure has recently been solved (46). This viral GPCR can signal via multiple different
G-alpha proteins, and this signaling is modulated by cell type and cytokine binding
(47–51) to activate a number of different signaling pathways (52–59). US28 signaling
can be modulated by binding of either CC or CX3C chemokines (52, 59–61), and
high-afﬁnity chemokine binding to US28 is known to be mediated by its N-terminal
domain (51); one point mutation to US28, US28-Y16F, greatly reduces chemokine
binding for RANTES and fractalkine (59).
During lytic infection, US28 is known to promote proliferative signals, including MAP
kinase and NF-B (48, 49, 57, 62), both of which are known to activate the MIEP (63, 64),
and its expression has also been linked to vascular disease and oncomodulation (52, 65,
66). This signaling by US28 during lytic infection requires G protein binding via the
highly conserved DRY motif of US28 that is found in most GPCRs and all CCRs (67);
consistent with this, a point mutation in this DRY motif of US28 (US28-R129A) greatly
reduces G-protein binding and ablates US28 signaling capability (48, 54, 68, 69).
Similarly, the US28 C terminus is also heavily phosphorylated and this is also known to
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modulate US28 signaling (70–72). All these known activator functions of US28 during
lytic infection, however, appear to be totally inconsistent with the observation that
US28 is required to enforce MIEP silencing during latency (21) and suggest very
different functions of US28 during latent infection and lytic infection.
In this work, we address this issue in detail by analyzing the effects of US28 seen
during HCMV latency. First, we show that, as with CD34 cells, US28 expression is also
necessary for the maintenance of HCMV latency in CD14 monocytes and that this
US28 activity is not dependent on US28 binding of chemokines but requires constitu-
tive G protein-coupled signaling. We also show that US28 has a signaling proﬁle in
undifferentiated monocytic cells that is completely different from that in differentiated,
macrophage-like cells; in undifferentiated myeloid cells, US28 attenuates multiple
different cell signaling pathways, including MAP kinase and NF-B signaling, and it is
the US28-mediated repression of these signaling pathways which helps US28 to repress
the MIEP, thereby maintaining latency. Consistent with this, treatment of latently
infected cells with a small-molecule inhibitor of US28 resulted in induction of IE
expression and virus release. Finally, we demonstrate that monocytes infected with
HCMV lacking US28 or treated with US28 inverse agonists and which consequently
express viral IE proteins are recognized and killed by preexisting HCMV-speciﬁc T cells
from HCMV-seropositive donors and propose that small-molecule inhibition of US28
could be a novel shock-and-kill approach for targeting latent HCMV for existing host T
cell responses.
RESULTS
US28 is required for HCMV to establish latency in monocytes. Latent infection
with HCMV is characterized by the expression of latency-associated genes, by little
concomitant lytic immediate early (IE) gene expression (32), and by the absence of
production of infectious virions. As expected, infection of monocytes after 7 days with
a clinical isolate of HCMV, the wild-type Titan strain (Titan-WT), which has a UL32-green
ﬂuorescent protein (UL32-GFP) tag that is expressed only at late times of lytic infection,
resulted in a characteristically latent infection—with high levels of expression of viral
UL138, a known latency-associated transcript, and with little accompanying IE72 or late
UL99 RNA (Fig. 1A). Similarly, these Titan-WT-infected cells did not show any IE72 or late
UL32-GFP protein expression (Fig. 1B, left panels) and did not produce infectious virions
in analyses performed by coculture on indicator ﬁbroblasts (Fig. 1C). In contrast,
infection of monocytes with a virus in which US28 had been deleted (Titan-ΔUS28)
showed high levels of IE72 RNA and concomitant expression of UL99 RNA, a true late
gene transcript (Fig. 1A), when infected with similar amounts of virus, as assessed by
genome copy quantitative PCR (qPCR) analysis (see Fig. S1 in the supplemental
material). To conﬁrm the expression of IE72 and late proteins in these cells, we also
stained the infected monocytes for IE72 protein and the late gene UL32-GFP protein
and observed clear evidence of expression of IE and UL32 proteins (Fig. 1B, right
panels). Finally, we cocultured these monocytes with indicator ﬁbroblasts to quantify
any virus release and also observed the presence of infectious virus in monocytes
infected with Titan-ΔUS28 virus but not in those infected with Titan-WT virus (Fig. 1C).
Consistent with viral lytic replication occurring only in Titan-ΔUS28-infected monocytes,
increases in viral genome copy numbers were detected in Titan-ΔUS28-infected mono-
cytes but not Titan-WT-infected monocytes 7 days postinfection (Fig. S1).
Taken together, these data argue for a requirement for US28 in either establishment
or maintenance of latent infection of CD14 monocytes and show that, in the absence
of US28, monocytes undergo full lytic infection.
Lytic infection of monocytes by Titan-US28 virus does not result from early
induction of myeloid differentiation. Having established that infection of CD14
monocytes with Titan-ΔUS28 for 7 days resulted in a lytic rather than a latent infection,
we wanted to rule out the possibility that US28 was simply maintaining a latent
infection by actively suppressing myeloid cell differentiation. We reasoned that if this
were the case, and if an absence of US28 simply induces infected monocytes to
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differentiate and to become fully permissive for HCMV lytic infection, there ought to be
a temporal delay in the induction of lytic gene expression in monocytes infected with
Titan-ΔUS28 to allow time for differentiation to occur. Consequently, we assayed for IE
mRNA and protein expression in monocytes infected with Titan-WT or Titan-ΔUS28 but
at very early time points postinfection. These analyses clearly showed that substantial
levels of lytic IE gene expression were observed as early as 12 h postinfection of
monocytes with Titan-ΔUS28 (Fig. 2A). We were also able to detect IE protein expres-
sion by immunoﬂuorescent (IF) microscopy from as early as 24 h postinfection (Fig. 2B)
and UL32-GFP expression from 48 h postinfection (Fig. 2C). Additionally, supernatants
from Titan-ΔUS28-infected monocytes, at 3 days postinfection, showed the presence of
infectious virus on indicator ﬁbroblasts (Fig. 2D). To further support those experiments,
we performed ﬂow cytometry analysis on monocytes infected with Titan-WT or Titan-
ΔUS28 for 7 days and observed little change in cell surface expression of CD14 or CD83,
each of which is a marker of differentiation (Fig. S2). All these data were entirely
consistent with the view that Titan-ΔUS28-infected monocytes immediately undergo a
lytic infection with little or no temporal delay and make it unlikely that infection in the
absence of US28 simply induced differentiation of monocytes to a cell phenotype that
is permissive for lytic infection.
US28 signaling maintains latency independently of chemokine binding. On the
basis of the observation that US28 appeared to be having a profound effect on the
outcome of infection of monocytes, supporting at least in part the establishment of
latency, we next decided to assess the effects of US28 expression on monocytic cells in
detail. To do this, we used lentiviral vectors to overexpress an N-terminally hemagglu-
FIG 1 Infection of monocytes with Titan-ΔUS28 results in lytic infection. CD14 peripheral blood monocytes were
isolated and experimentally infected at an MOI of 5 with HCMV Titan-WT or Titan-ΔUS28. (A) Seven days
postinfection, RNA from these cultures was harvested and analyzed for expression of the latency-associated UL138
gene, the major immediate early lytic IE1 gene, and the major late UL99 gene. Data were normalized to GAPDH
RNA. (B) Seven days postinfection, monocytes were also ﬁxed and stained for IE protein and UL32-GFP (using an
antibody against the GFP tag). (C) These monocyte cultures were then cocultured with HFFs, and the number of
infected HFFs was measured by staining for cells expressing HCMV IE protein at 72 h postcoculture. All data points
show means of results from at least four independent experiments; error bars show standard deviations. *, P 0.05
(statistically signiﬁcant result; calculated using Student’s t test).
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tinin (HA)-tagged US28 (HA-US28-WT) (73) in isolation in the monocytic THP-1 cell line
which we and others have used as a model of latent HCMV infection (42, 74, 75). At the
same time, we also overexpressed two HA-tagged US28 mutants, namely, HA-US28-
R129A and HA-US28-Y16F, which have ablated signaling and chemokine binding
function, respectively (Fig. 3A).
We then infected these THP-1 cell lines, stably expressing HA-US28-WT, HA-US28-
R129A, or HA-US28-Y16F proteins, with Titan-ΔUS28 virus to assess whether supplying
these US28 proteins in trans would affect the ability of Titan-ΔUS28 to undergo a lytic
infection in these undifferentiated monocytic cells.
Figure 3B shows that, as expected, control THP-1 cells stably transduced with an
empty vector underwent lytic infection when infected with Titan-ΔUS28 virus, in that IE
and UL32-GFP proteins were detectable. In contrast, expression of HA-US28-WT in
THP-1 cells complemented the lack of US28 in Titan-ΔUS28 virus and this resulted in
cells negative for IE and UL32-GFP expression—consistent with a latent infection.
Interestingly, THP-1 cells expressing the HA-US28-R129A protein failed to complement
the Titan-ΔUS28 virus mutation (these infected cells were IE and UL32-GFP positive),
whereas infection of THP-1 cells stably expressing the HA-US28-Y16F mutant also
complemented Titan-ΔUS28 virus and resulted in cells undergoing latent infection (as
detected by a lack of IE and UL32-GFP expression) (Fig. 3B). Also as expected, THP-1
cells infected with Titan-WT showed little lytic gene expression, regardless of expres-
sion of any HA-US28 construct (Fig. S3).
FIG 2 Titan-ΔUS28 virus initiates lytic infection immediately after infection of CD14 monocytes. CD14 peripheral blood
monocytes were isolated and experimentally infected at an MOI of 5 with HCMV Titan-WT or Titan-ΔUS28. (A) Twelve hours
postinfection, RNA from these cultures was harvested and analyzed by RT-qPCR for the latent UL138 gene and the lytic IE and
UL99 genes. Data were normalized to GAPDH RNA. (B) One day postinfection, monocytes were ﬁxed and stained for IE protein.
(C) Two days postinfection, monocytes were ﬁxed and stained for IE or UL32-GFP protein. (D) Each day postinfection, medium
was harvested from monocytes infected with Titan-WT or Titan-ΔUS28 and titrated onto indicator HFFs. These were
subsequently stained for HCMV IE protein, as a measure of viral titers, 24 h postinfection. All data points show means of results
from at least four independent experiments; error bars show standard deviations.
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We also tested whether any observed failure to complement Titan-ΔUS28 by these
US28 constructs, which resulted in lytic gene expression, also resulted in production of
infectious virus. Figure 3C shows that cells in which IE and late gene expression could
be detected also produced infectious virions, as expected.
Finally, we conﬁrmed that the ability of HA-US28-WT and HA-US28-Y16F to com-
plement Titan-ΔUS28 and to establish latent infection resulted in cells from which
HCMV could be reactivated by differentiation (Fig. S4). Taken together, these data
suggest that the ability of US28 to suppress lytic infection likely resides in its down-
stream signaling, via G protein activation, and that this signaling occurs independently
from chemokine binding.
US28 suppresses or activates the MIEP depending on the differentiation status
of the monocytic cell. As US28 signaling appeared to be necessary for the establish-
ment of latency in monocytes, we hypothesized that US28 expression likely negatively
regulates the MIEP in undifferentiated monocytic cells. To test this, we used THP-1 cell
lines that had been transduced with an MIEP-enhanced GFP (MIEP-eGFP) construct (76)
to transfect these cells by nucleofection with three HA-US28 constructs and with the
empty vector control (Fig. S5). Two days posttransfection, we measured eGFP expres-
sion in these cell lines by ﬂow cytometry. Figure 4A shows that, consistent with a role
for suppression of lytic infection in undifferentiated THP-1 cells, HA-US28-WT did,
indeed, show repression of MIEP activity, as did the HA-US28-Y16F mutant. In contrast,
the HA-R129A-US28 signaling mutant showed no such repression. We also repeated
FIG 3 Ectopic US28 expression in THP-1 cells can complement for a deletion of US28 from the virus. THP-1 cells stably
expressing N-terminally HA-tagged US28 (HA-US28-WT), US28 with a disrupted G protein binding DRY motif (HA-US28-R129A),
and US28 with a disrupted chemokine binding region (HA-US28-Y16F) were generated by lentiviral transduction and
puromycin selection. (A) Western blot analysis using an antibody against the N-terminal HA tag was carried out on an
empty-vector-transduced cell line and the three cell lines expressing HA-US28 constructs. (B) These THP-1 cells, expressing
different HA-US28 constructs and empty vector control cells, were infected with Titan-ΔUS28 and ﬁxed 5 days postinfection.
Fixed samples were stained for immediate early or UL32-GFP and nuclei were also stained. (C) Media from these infected cells
was titrated on indicator ﬁbroblasts and the number of infectious virions quantiﬁed by IE staining. Data are means of results
from at least three independent experiments; error bars show standard deviations.
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this analysis, but, 2 days after nucleofection with the HA-US28 constructs and empty
vector control, we differentiated the THP-1 cells with phorbol myristate acetate (PMA)
(Fig. 4B). In contrast to the results seen with undifferentiated THP-1 cells, HA-US28-WT
and HA-US28-Y16F now activated the MIEP, whereas HA-US28-R129A expression had
no signiﬁcant effect on MIEP activity. These data conﬁrm that the effect of US28 on IE
gene expression is differentiation dependent; US28 appears to repress the MIEP in
undifferentiated monocytic cells, consistent with a role of US28 in maintaining latency,
but activates the MIEP after cellular differentiation, likely to promote lytic infection.
US28 attenuates MAP kinase and NF-B cell signaling pathways. US28 expres-
sion during lytic infection is known to activate a number of cell signaling pathways,
including the NF-B and MAP kinase pathways, both of which are known to activate the
MIEP in fully permissive cells. To analyze the potential effect of US28 on such signaling
during latent infection, we used phosphokinase antibody arrays to assess whether US28
mediates changes in phosphorylation of an array of different cellular signaling proteins
(Fig. 5). Speciﬁcally, we compared THP-1 cells expressing either HA-US28-WT or the
HA-US28-R129A signaling mutant; we reasoned that comparing HA-US28-WT to the
HA-US28-R129A signaling mutant would robustly control for potential nonspeciﬁc
effects of US28 protein overexpression. These analyses showed that HA-US28-WT
speciﬁcally decreased the phosphorylation of a number of cellular proteins, suggesting
a general attenuation of cell signaling pathways by wild-type US28 in undifferentiated
monocytic cells. In particular, we noted signiﬁcant reductions in the phosphorylation
levels of several key signaling proteins, chief among them being ERK1/2 of the MAP
kinase pathway (Fig. 5).
Our result, showing that US28 mediated suppression of MIEP activity as well as
inhibiting ERK1/2, ﬁts well with the view that MAP kinase signaling is likely involved in
HCMV reactivation (23). Consequently, we validated the results of the phosphokinase
array by performing Western blotting on three cellular proteins that are key to the MAP
kinase signaling pathway: ERK1/2, mitogen and stress activated kinase (MSK-1), and
cAMP response binding element-binding protein (CREB). Figure 6A to C (left panels)
shows that all three proteins were hypophosphorylated in THP-1 cells expressing
HA-US28-WT compared to control cells expressing HA-US28-R129A. As US28 is associ-
ated with activation of MAP kinase during lytic infection, we also repeated this analysis
in these THP-1 cells after they had been differentiated to a macrophage-like phenotype
(which is permissive with respect to HCMV lytic infection) (6,8,9,12). Figure 6 shows that
overexpression of US28 now had the opposite effect on ERK1/2, MSK-1, and CREB
phosphorylation; HA-US28-WT protein resulted in their hyperphosphorylation com-
pared to the results seen with cells expressing HA-US28-R129A (Fig. 6A to C).
FIG 4 US28 represses the MIEP in undifferentiated myeloid cell lines but activates it in differentiated
myeloid cells. (A) THP-1 cells which had been transduced with an MIEP-eGFP construct were then
transfected by nucleofection with HA-US28-WT, HA-US28-R129A, or HA-US28-Y16F constructs.
Three days after nucleofection, cells were analyzed for eGFP expression by ﬂow cytometry. (B) Addition-
ally, cells were treated with PMA 2 days after nucleofection and were analyzed by ﬂow cytometry 2 days
after treatment. Data show percentages of change in mean ﬂuorescent intensities from four technical
replicates, after selection for single cells and exclusion of dead cells using Zombie red dye. Error bars
show standard deviations. P values of 0.05 (*) and 0.01 (**) were calculated using Student’s t test and
were considered signiﬁcant.
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Finally, we performed nuclear/cytoplasmic fractionation followed by Western blot-
ting to analyze the effect of US28 on NF-B activation (Fig. 6D). These analyses showed
that the NF-B pathway is also attenuated by US28 in undifferentiated monocytic THP-1
cells in that, in contrast to the results seen with HA-US28-R129A or control vector, US28
expression resulted in a relative lack of nuclear localization of p65 (Fig. 6D, left panels).
As predicted, this was reversed in differentiated THP-1 cells (Fig. 6D, right panels).
Inhibition of MAP kinase and NF-B cell signaling pathways can reduce lytic
infection of monocytes by Titan-US28 virus. On the basis of the ﬁndings that US28
expression, in isolation in undifferentiated myeloid cells, attenuates MAP kinase and
NF-B signaling pathways and that this correlates with the suppression of the MIEP and
the ability of HCMV to establish latency, we reasoned that we should be able to mimic
the action of US28 in undifferentiated CD14 monocytes by inhibiting MAP kinase
and/or NF-B signaling, in the context of HCMV infection; in essence, we reasoned that
we could compel Titan-ΔUS28 virus to establish latency in monocytes by pretreating
these monocytes with inhibitors of either MSK-1 or IB kinase (IKK) (using H89 or
Bay11-7082, respectively) before infection. To test this, we treated cells with inhibitors
prior to infection with Titan-ΔUS28 and then measured the number of UL32-GFP-
positive cells 3 days postinfection, as an indicator of full, lytic infection. Figure 7A
and B show that neither inhibitor alone was able to prevent Titan-ΔUS28 virus from
undergoing lytic infection. However, infection in the presence of both inhibitors
together did, indeed, lead to an absence of UL32-GFP gene expression in Titan-ΔUS28-
infected monocytes in a dose-dependent manner and this could not be attributed to
nonspeciﬁc cell toxicity effects (Fig. 7C, black squares).
Our observations presented in Fig. 2 indicating that Titan-ΔUS28 virus initiated IE
expression in infected monocytes 6 to 12 h postinfection also suggested that US28 may
be required at very early times of HCMV infection of monocytes to suppress the MIEP
and help establish latency. Therefore, we hypothesized that, during infection with
HCMV virus, US28 protein expression likely blocks activation signals for the MIEP in
monocytes, which could occur due to virus binding or internalization. In order to test
FIG 5 US28 expression in THP-1 cells, in isolation, attenuates cellular signaling. THP-1 cells which had
been induced to express either US28-WT or US28-R129A (which cannot maintain latency) were lysed and
analyzed for changes in cellular kinase phosphorylation levels by antibody array. Data represent fold
change in dephosphorylation of each kinase from THP-1 cells expressing US28-WT over the levels
induced by THP-1 cells expressing US28-R129A. Data points in red represent results that showed a
change in intensity of  log2 (0.5) arbitrary units and/or a P value greater than log10 (1.5).
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this, we delayed inhibitor treatment of monocytes infected with Titan-ΔUS28 until
either 1 h or 1 day postinfection, assuming that delaying inhibition of MAP kinase and
NF-B would lead to the activation of the MIEP by viral entry and that this would no
longer be preventable once MIEP activity was fully established. Treatment of mono-
cytes with H89 and BAY11-7082 at 1 h postinfection was still effective at blocking lytic
infection by Titan-ΔUS28. However, when treatment was delayed until 1 day postin-
fection, the inhibitors were no longer as effective at blocking lytic infection (Fig. 7D and
E). These data suggest that signals triggered within the ﬁrst 24 h of infection of
monocytes by HCMV activate MIEP activity but that US28 attenuates these signals to
suppress IE expression in order to establish latent infection.
US28 attenuation of cellular signaling prevents phosphorylation of histone H3
and subsequent activation of the MIEP. It is well established that in undifferentiated
FIG 6 US28 expression in THP-1 cells, in isolation, attenuates MAP kinase and NF-B cellular signaling. (A) THP-1 cells expressing either HA-US28-WT or
HA-US28-R129A (which cannot maintain latency) or an empty vector control were lysed and analyzed by Western blotting for phospho- and total ERK1/2 and
beta-actin levels (left panels). THP-1 cells were also differentiated with PMA treatment and, at 4 days posttreatment, were analyzed by Western blotting for
phospho- and total ERK1/2 and beta-actin levels (right panels). (B and C) The same analysis was performed for phospho- and total MSK-1 in undifferentiated
cells (B, left panels) or 4 days after differentiation with PMA treatment (B, right panels) and also for phospho- and total CREB (C). (D) Cells were also fractionated
into nuclear and cytoplasmic fractions, and these fractions were subjected to Western blot analysis for NF-B protein (p65) before (left) and after (right)
differentiation. Nuclear protein p84 and cytoplasmic protein GAPDH were used as loading and fractionation controls for the respective fractions. (E) These blots
were subjected to densitometry analysis using ImageJ software, and the relative amounts of phosphoprotein (for panels A to C) or NF-B localization (for panel
D) were quantiﬁed against actin, GAPDH, or p84 loading controls.
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myeloid cells, the viral MIEP is associated with histone marks of transcriptional repres-
sion, including the presence of methylated histones and repressor proteins such as
heterochromatin protein 1 (HP1). In contrast, when this repression is relieved during
myeloid differentiation, the MIEP becomes associated with histone marks of transcrip-
tional activation such as the presence of acetylated histones and histone H3 phosphor-
ylation (7, 9, 12–17). It has also been established, more recently, that myeloid differ-
entiation activates CREB binding to the MIEP, causing corecruitment of MSK-1 and
subsequent phosphorylation of histone H3, which is known to destabilize the binding
of HP1 (23). We therefore hypothesized that US28-mediated attenuation of MSK-1 and
CREB signaling could prevent histone phosphorylation and activation of the MIEP,
thereby maintaining latency. Consequently, we infected monocytes with Titan-WT and
Titan-ΔUS28 and performed chromatin immunoprecipitation (ChIP) assays against HP-1
and H3-S10p, markers of histone repression and activation, respectively. As expected,
the MIEP was associated with HP-1 in monocytes latently infected with Titan-WT but
was associated with phosphorylated H3 in monocytes lytically infected with Titan-
ΔUS28 (Fig. 8). US28, therefore, appears to mediate parts of its repressive function via
prevention of destabilization of HP1 binding.
The US28 inhibitor VUF2274 can induce lytic infection in monocytes infected
with wild-type HCMV. VUF2274 (BX 513 hydrochloride) is an antagonist of CCR1 and
FIG 7 Inhibition of MAP kinase and NF-B pathways can prevent lytic infection of monocytes by
Titan-ΔUS28. (A) CD14 peripheral blood monocytes were isolated and infected at an MOI of 5 with
Titan-ΔUS28 in the presence of increasing concentrations of H89 (an inhibitor of MSK-1). Subsequently,
GFP-positive cells were counted 3 days postinfection and cell survival was measured by trypan blue
exclusion staining. (B) Monocytes were infected with Titan-ΔUS28 in the presence of titrations of BAY11-
7082 (an inhibitor of IKK). Subsequently, GFP-positive cells were counted 3 days postinfection and cell
survival was measured by trypan blue exclusion staining. (C) Monocytes were treated with both H89 and
BAY11-7082 and then infected with Titan-ΔUS28 in the presence of both inhibitors. Subsequently, GFP-
positive cells were counted 3 days postinfection and cell survival was measured by trypan blue exclusion
staining. (D) Monocytes were infected with Titan-ΔUS28, but treatment with H89 and BAY11-7082 was
delayed until 1 h postinfection. Subsequently, GFP-positive cells were counted 3 days postinfection and cell
survival was measured by trypan blue exclusion staining. (E) Monocytes were infected with Titan-ΔUS28,
but treatment with H89 and BAY11-7082 was delayed until 1 day postinfection. Subsequently, GFP-positive
cells were counted 3 days postinfection and cell survival was measured by trypan blue exclusion staining.
All data points show means of results from at least three independent experiments; error bars show
standard deviations.
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an inverse agonist of US28 (77). Given that our results obtained so far showed that US28
signaling was required to help establish latency in monocytes, we predicted that
monocytes infected with wild-type HCMV in the presence of VUF2274 would trigger
viral lytic gene expression and, possibly, virus reactivation. To test this, we latently
infected monocytes for 3 days with RV1164, an isolate of HCMV that has an IE2-yellow
ﬂuorescent protein (IE2-YFP) tag, and then treated them with a titration of VUF2274 and
quantiﬁed IE protein expression by counting YFP-positive monocytes 3 days after drug
treatment (Fig. 9A). We also quantiﬁed any production of infectious virus in these
cultures treated with VUF2274 by removing media from monocytes 3 days post-drug
treatment and titrating this media onto indicator ﬁbroblasts (Fig. 9B). As predicted,
VUF2274 treatment did induce IE gene expression (Fig. 9A) and resulted in measurable
release of virus from these reactivated cells (Fig. 9B). Consistent with this, equivalent
experiments using infection with Titan-WT, which has a UL32-GFP tag, also conﬁrmed
late gene expression (UL32) in these VUF2274-treated cells (Fig. 9C). Taken together,
these data argue that inhibition of US28 signaling by VUF2274 appears to reactivate full
lytic gene expression and lytic infection in monocytes latently infected with wild-type
HCMV. It should be pointed out, however, that VUF2274 did show signiﬁcant toxicity (as
measured by trypan blue staining) for primary blood monocytes, even at concentra-
tions below an approximate Ki value of 10 M (Fig. 9D). Additionally, as expected,
although attenuation of cellular signaling by US28 can be inhibited by VUF2274,
leading to activation of MIEP and IE protein expression, this signaling to MIEP can be
blocked by simultaneous inhibition of MSK-1 and NF-kB (Fig. S6).
Monocytes infected with Titan-US28 virus are targets for killing by preexist-
ing HCMV-speciﬁc donor cytotoxic T cells. It is well established that, after primary
infection, healthy HCMV carriers maintain extremely high frequencies of HCMV-speciﬁc
CD8 cytotoxic T lymphocytes (CTLs) in their peripheral blood which are often domi-
nated by CTLs which recognize IE antigens; up to 10% of effector memory CD8 CTLs
can recognize IE72 in some donors (78–80). However, because latently infected cells
express only small amounts of these lytic antigens, they escape these HCMV-speciﬁc
CTL responses. We therefore reasoned that the inability of Titan-ΔUS28-infected mono-
cytes to undergo latent infection, and their resulting high level of lytic gene expression,
should make them targets for preexisting HCMV-speciﬁc CTLs in the peripheral blood
of healthy HCMV carriers. The same would be observed in monocytes latently infected
with wild-type virus if US28 were inhibited by VUF2274. Figure 10A shows that
coculture of monocytes infected with Titan-ΔUS28 with donor-matched IE72-speciﬁc T
cell clones resulted in a reduction in the frequency of reactivation of latently infected
cells from these infected monocytes after their differentiation and maturation to
FIG 8 The MIEP is associated with phosphorylated serine-10-H3 in the absence of US28. CD14
monocytes were infected with either Titan-WT or Titan-ΔUS28. The cells were harvested 6 days postin-
fection for ChIP analysis (using a Sigma Imprint ChIP kit). The MIEP was precipitated with either anti-HP1
(HP1 antibody [FL-191]: sc-28735) or anti-ser-10-H3 (phospho-histone H3 [Ser10] antibody [9H12L10],
ABﬁnity Rabbit Monoclonal) or the isotype control (ISO). The MIEP was quantitated against a standard
curve of viral DNA and analyzed by qPCR, and the results were then plotted as a percentage of input
DNA, with each sample run in triplicate.
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mature dendritic cells (mDCs). As expected, we also found that treatment with IE-
speciﬁc T cells resulted in a reduction in the level of virus release from monocytes
infected with Titan-ΔUS28, due to killing of these lytically infected cells in the absence
of their differentiation and maturation (Fig. 10B). We also repeated this analysis with
donor-matched total peripheral blood mononuclear cells (PBMCs), instead of IE-72
speciﬁc T cell clones, in order to show that the in vivo HCMV-speciﬁc host immune
response is also able to kill Titan-ΔUS28-infected monocytes; we saw reductions in the
levels of virus reactivation events from monocytes infected with Titan-ΔUS28 similar to
the levels seen with those infected with Titan-WT after their subsequent differentiation
and maturation (Fig. 10C).
To conﬁrm that these observations were a result of T cell killing rather than, for
instance, repression of GFP expression, we also incubated monocytes infected with
Titan-WT or Titan-ΔUS28 with isolated CD8 T cells from matched donors and analyzed
T cell-speciﬁc increases in the levels of two markers of T cell activation, CD69 and 4-1BB,
by ﬂow cytometry to assay for CMV-speciﬁc CD8 T cell responses. The CD8 T cells
exposed to Titan-ΔUS28-infected monocytes were more highly activated than those
exposed to monocytes latently infected with Titan-WT (Fig. 10D). As a readout of the
functional capacity of these CMV-speciﬁc CD8 T cells, we also analyzed their produc-
tion of the cytokines gamma interferon (IFN-) and tumor necrosis factor alpha (TNF-)
as well as upregulation of degranulation marker CD107a and expression of granzymes
A, B, and K. Figure 10E shows that, by the use of these functional effector markers, CD8
T cells clearly recognized Titan-ΔUS28-infected monocytes but not Titan-WT-infected
monocytes. We also conﬁrmed that monocytes latently infected with Titan-WT virus can
FIG 9 VUF2274 is able to induce reactivation of HCMV from latently infected monocytes. CD14
peripheral blood monocytes were isolated and infected at an MOI of 5 with RV1164, which has an IE2-YFP
ﬂuorescent tag. Three days postinfection, increasing concentrations of the US28 inhibitor VUF2274 were
added to cells. (A) IE2-YFP-positive cells were counted by immunoﬂuorescent microscopy at 72 h
posttreatment. (B) Five days post-drug treatment, medium was removed from these cells and titrated
onto HFFs. Three days postinfection, HFFs were ﬁxed and stained for IE protein, and IE-positive cells were
counted by immunoﬂuorescence microscopy. (C) CD14 peripheral blood monocytes were isolated and
infected at an MOI of 5 with Titan-WT. Three days postinfection, increasing concentrations of the US28
inhibitor VUF2274 were added to cells. Five days post-drug treatment, UL32-GFP-positive cells were
counted by ﬂuorescence microscopy. (D) Cell survival of monocytes in the presence of VUF2274 for
4 days was measured using trypan blue exclusion staining. All data points show means of results from
three replicates, and error bars show standard deviations. Data were subjected to analysis of variance
(ANOVA) followed by Tukey’s post hoc test. *, P  0.05 (statistically signiﬁcant result).
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act as targets for CTLs; the levels of expression of CD107a as well as the levels of
production of granzymes, IFN-, and TNF- by CMV-speciﬁc CD8 T cells in response
to the Titan-ΔUS28 virus were equivalent to the levels seen in response to monocytes
which had been infected with Titan-WT virus and pulsed with IE1/2 peptides as
positive-control targets for CMV-speciﬁc CD8 T cell responses. These data, taken
together, argue that monocytes infected with Titan-ΔUS28 are robustly detected by
preexisting CD8 T cells in HCMV-seropositive donors.
Finally, we tested whether treatment of latently infected cells with VUF2274 also
made them targets for IE72-speciﬁc CTLs. Figure 10F shows that, consistent with
previous analyses (37, 73, 81), monocytes latently infected with simian virus 40-GFP-
TB40E (SV40-GFP-TB40E) were detectable as GFP cells and that their numbers re-
FIG 10 Monocytes infected with Titan-ΔUS28 or monocytes infected with SV40-GFP-TB40E in the presence of US28 inhibitors are targets for HCMV-speciﬁc
T cell responses. (A) CD14 monocytes were infected with either Titan-WT or Titan-ΔUS28. Three days postinfection, monocytes were cocultured with
IE72-speciﬁc T cells for a further 3 days. After this, monocytes were washed to remove T cells and monocytes were then differentiated and matured to induce
virus reactivation. Reactivated virus was quantiﬁed by ﬁbroblast coculture and staining for IE foci. (B) Monocytes were removed from media from the experiment
described for panel A at 3 days after T cell treatment and titrated onto ﬁbroblasts to quantify virus release from Titan-ΔUS28-infected monocytes. (C) CD14
monocytes from seropositive donors were infected with either Titan-WT or Titan-ΔUS28, and the nonmonocyte PBMCs were added back to the infected
monocytes 3 days postinfection for 4 days and then removed by washing. The remaining adherent monocytes were then differentiated and matured to induce
virus reactivation. Reactivated virus was quantiﬁed by ﬁbroblast coculture and staining for IE foci. (D) CD14monocytes from seropositive donors were infected
with either Titan-WT or Titan-ΔUS28, and, 5 days postinfection, latent monocytes were left untreated or cocultured overnight with isolated CD8 T cells from
the same donor and analyzed for expression of the activation markers CD69 and 4-1BB and for expression of the following degranulation markers: CD107a;
granzymes A, B, and K; TNF-; and IFN-. Data in panel D represent the percentage of CD8 T cells expressing both activation markers, above background
stimulation levels, in response to either Titan-WT-infected or Titan-ΔUS28-infected monocytes. (E) The proportions of HCMV-speciﬁc CD8 T cells expressing
degranulation markers seen with those activated monocytes are shown, as are those of CD8 T cells stimulated with virus-infected monocytes and pulsed with
IE1/2 peptides as antigen-speciﬁc positive controls. (F) Monocytes from an HLA-A2-positive donor were latently infected with SV40-GFP-TB40E and were left
untreated or treated with VUF2274 3 days postinfection. Two days posttreatment with drug, monocytes were cocultured with IE72-speciﬁc T cells, following
which monocytes expressing GFP were counted over the subsequent 4 days. Data points for all panels show means of results from at least three independent
experiments; error bars show standard deviations.
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mained relatively constant when cultured with IE72-speciﬁc CTLs. In contrast, when
these latently infected monocytes (GFP cells) were treated with VUF2274, a steady
reduction of the number of latently infected cells was observed in these IE72-speciﬁc
CTL cocultures (Fig. 10F). Unfortunately, due to the long-term toxicity of VUF2274, we
were not able to show that this also resulted in a subsequent reduction in reactivation
events after monocyte differentiation and maturation to mDCs.
Taken together, these data suggest that the preexisting CTL response to HCMV, in
healthy carriers, is able to target and kill monocytes infected with Titan-ΔUS28 and that
the treatment of latently infected monocytes with US28 inhibitor VUF2274 also makes
them novel CTL targets. On this basis, we suggest that inhibition of US28 with, for
instance, small-molecule inhibitors could result in untimely reactivation of latent virus
and could allow their targeting by preexisting HCMV-speciﬁc host T cell responses.
DISCUSSION
HCMV latency and reactivation of virus from latency pose signiﬁcant clinical threats
to immunosuppressed transplant recipients and other immunocompromised individ-
uals (82). However, there are currently only a few published strategies for treatment of
HCMV latency (17, 40, 73). HCMV establishes latent infection in early myeloid lineage
cells (4), where its latent life cycle is characterized by expression of only a small subset
of viral genes independently of viral IE gene expression. This includes expression of the
viral chemokine receptor homologue US28 (35, 83). US28 expression during HCMV lytic
infection is well established to activate multiple cell signaling pathways which can
activate the viral MIEP (48, 52–57). These signals have previously been linked to vascular
diseases as well as to oncomodulation (53, 65, 66). However, this powerful signal
activation appears to contrast with the recently identiﬁed requirement for US28
expression to establish a latent infection in CD34 stem cells, likely by repressing viral
IE gene expression (21).
Here, we conﬁrm this important function of US28 during latent infection in CD14
monocytes and, in part, solve this paradox by showing that US28 appears to have very
different effects on cell signaling in undifferentiated and differentiated cells. US28
attenuates cellular signaling of MAP kinase and NF-B in undifferentiated cells, which
supports epigenetic suppression of the MIEP to prevent lytic infection. In contrast, US28
activates these same signaling pathways in differentiated myeloid cells to help drive IE
expression and virus reactivation. Our analysis, using a viral isolate with a deletion for
the US28 gene, showed that US28 was necessary for the maintenance of HCMV latency
in monocytes; monocytes infected with Titan-ΔUS28 underwent full lytic infection and
produced infectious virus.
These initial analyses were made 7 days postinfection. Interestingly, repeating this
analysis at early times postinfection indicated that this ability of Titan-ΔUS28 to initiate
a lytic infection in monocytes was immediate and did not require time for monocytes
to become differentiated to a macrophage/DC phenotype, arguing that US28 does not
function by suppressing myeloid differentiation and subsequent viral reactivation. We
observed IE mRNA expression at 12 h postinfection, IE protein expression at 24 h
postinfection, and UL32-GFP expression at 48 h postinfection, indicating that infection
of monocytes by Titan-ΔUS28 undergoes a time course of gene expression similar to
that seen with lytic infection of ﬁbroblasts. Additionally, we did not see changes in cell
surface markers of myeloid differentiation 7 days postinfection with Titan-ΔUS28. This
suggests that, in the absence of US28 protein, monocytes themselves can support lytic
HCMV infection and that differentiation of monocytes is not necessary for lytic infection
under these conditions.
Complementation analyses in THP-1 cells stably expressing US28 functional muta-
tions gave us substantial insight into the mechanisms by which US28 suppressed lytic
infection of monocytes. Infection with Titan-ΔUS28 of THP-1 cell lines stably expressing
different US28 mutants, including wild-type US28 protein (HA-US28-WT), US28 protein
which cannot signal (HA-US28-R129A), and US28 protein which cannot bind chemo-
kines (HA-US28-Y16F), showed that US28 maintains latency by G protein-mediated
Krishna et al. ®
November/December 2017 Volume 8 Issue 6 e01754-17 mbio.asm.org 14
signaling and that this signaling occurs in a constitutive manner, independently of
chemokine binding. These observations ﬁtted well with analyses of the effect of US28
on the MIEP in transfection assays. Nucleofection of our HA-US28 constructs into THP-1
cells which had been transduced by lentivirus to express eGFP driven by the MIE
promoter conﬁrmed that HA-US28-WT repressed the MIEP in a signaling-dependent
manner and further showed that, in differentiated THP-1 cells, the activity of US28
switched from that of a repressor, as seen in undifferentiated monocytic cells, to that
of an activator of the MIEP and that this, too, was dependent on the US28 signaling
capacity. This was entirely consistent with data from other permissive cell types which
have consistently shown the ability of US28 to activate IE expression (63, 64). Our view,
that the regulation of IE expression by US28 was likely signaling dependent, was
conﬁrmed by our observations indicating that US28 profoundly affected the level of a
number of cellular phosphokinases. In undifferentiated monocytic cells, HA-US28-WT
signiﬁcantly attenuated the MAP kinase pathway; in particular, ERK1/2, MSK-1, and
CREB were all less phosphorylated. Similarly, consistent with the observation that US28
has an activation effect on the MIEP in cells that are permissive for HCMV lytic infection
(52, 63, 64), US28 activated MAP kinase signaling in differentiated monocytic cells and
this is diametrically opposite its suppressive effect in undifferentiated monocytic cells.
US28 also differentially affected NF-B localization in undifferentiated and differenti-
ated monocytic cells; US28 resulted in increased cytoplasmic NF-B localization in
undifferentiated cells but enhanced NF-B nuclear localization in differentiated cells.
This, again, is consistent with the known NF-B-mediated activation of the MIEP (63)
and helps explain the differentiation-dependent reversal of US28 activity with respect
to the chromatin-mediated control of MIEP activity and IE gene expression in undif-
ferentiated or differentiated monocytic cells, which suppress or support IE gene ex-
pression, respectively. Taking the data together, it appears that US28 activity in early
myeloid lineage cells serves to maintain latency by attenuating reactivation signals,
such as MAP kinase (23) and NF-B, which are both known to activate the MIEP either
directly or via release of chromatin-mediated suppression around the MIEP (23, 47, 63,
84, 85). We were able to observe this change in activation and repressive chromatin
marks on the MIEP by ChIP assay at the level of H3 phosphorylation and HP1 recruit-
ment. This radical differentiation-dependent reversal of US28 activity helps resolve the
problem of why US28, considered to be a strong activator of cellular signaling in lytic
infection, is also expressed during latency, when lytic infection is known to be actively
suppressed.
How US28 apparently reverses its signaling properties between undifferentiated and
differentiated myeloid cells in such a signiﬁcant manner remains unclear. US28 has
been investigated in a range of different cell types, but its effects on different cell types
have not always been consistent (56, 65). Our observations appear to represent the ﬁrst
evidence that US28 can attenuate cell signaling, independently from other viral GPCRs,
in a constitutive manner, at least in undifferentiated myeloid cells. Two models may
explain these observations. First, phosphorylation of the C-terminal tail of US28 is
known to modify its signaling properties (70–72), and US28 is known to be phosphor-
ylated by protein kinase C (PKC) (71), showing isoform changes during myeloid cell
differentiation (86). It is, therefore, possible that changes in cellular kinase expression
that occur during myeloid differentiation alter US28 signaling by its differentiation-
dependent phosphorylation. Alternatively, US28 is known to interact promiscuously
with a range of different G-alpha proteins (47, 49, 50); similarly, changes in cellular
G-alpha protein expression are known to occur during myeloid differentiation. Conse-
quently, differentiation-speciﬁc changes in the G-alpha protein interactions with US28
could lead to changes in the signaling properties of US28.
More recently, US28 has been shown to activate PLC- in monocytes (58), via G
protein-coupling, in a chemokine-independent manner, which suggests that attenua-
tion of the MAP kinase and NF-B signaling pathways may not be the only mechanism
by which US28 may affect IE expression differently in undifferentiated and differenti-
ated monocytic cells. Given that histone deacetylase (HDAC) inhibitors induce IE gene
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expression in otherwise latently infected monocytes but do not trigger full, lytic gene
expression or virus production in treated monocytes (17), it appears that major IE
protein expression alone in monocytes is not sufﬁcient to induce full virus production.
Since deletion of the US28 gene causes full lytic gene expression, US28 is likely to have
functions beyond just repression of the MIEP.
Our attempts to reproduce US28-mediated attenuation of the lytic cycle in undif-
ferentiated cells, using small-molecule inhibitors of either MAP kinase or NF-B in
isolation, had only a limited effect on the ability of Titan-ΔUS28 to establish lytic
infection of monocytes. However, concomitant inhibition of MAP kinase and NF-B
signaling pathways profoundly reduced lytic gene expression in Titan-ΔUS28-infected
monocytes. Our view is that lytic infection, via activation of the MIEP, can be stimulated
by either MAP kinase or NF-B signaling but requires activation of at least one of these
two pathways. Our observation that delaying this treatment of inhibitors until 24 h
postinfection no longer prevented lytic infection demonstrates that US28 has to act at
a very early time point postinfection to suppress activation signals to the MIEP and thus
prevent lytic infection. We believe that these activation signals are likely triggered by
viral binding or entry into the cell, perhaps triggering innate immune responses, which
could lead to the activation of the MIEP (87, 88), and that US28 may serve to attenuate
this response and thereby stiﬂe IE activation to help initiate viral latency.
Finally, on the basis of our ﬁndings that US28 is crucial to establish HCMV latency in
monocytes by suppressing IE gene expression and subsequent lytic infection, we
predicted that inhibition of US28 activity, using its inverse agonist VUF2274, would
stimulate lytic gene expression in normally latently infected monocytes. This was
indeed the case and led to a proof of principle that inducing lytic infection in
monocytes could lead to their targeting by preexisting host HCMV-speciﬁc CTL re-
sponses. First, IE72-speciﬁc CD8 T cell clones reduced viral reactivation from mono-
cytes infected with Titan-ΔUS28 compared to monocytes infected with Titan-WT virus;
second, similarly, treatment of experimentally latent monocytes with VUF2274 also
made latently infected cells targetable by these IE72-speciﬁc CD8 T cell clones. We
also demonstrated that monocytes infected with Titan-ΔUS28 are targets for PBMCs
from healthy HCMV-positive donors and conﬁrmed that this was mediated by classical
CTL killing on the basis of staining for markers of T cell activation and degranulation.
Although this approach of “shock and kill,” using HDAC inhibitors, has already been
demonstrated to be effective against latent HCMV (17), HDACs have a wide range of
biological functions and the inhibition of HDACs could have signiﬁcant off-target
effects. Consequently, an inhibitor of US28 usable for “reactivation” of IE expression
could be an attractive alternative, particularly in healthy seropositive tissue donors
where reactivation events are thought to be subclinical (89, 90). We do note that
VUF2274 did show some cytotoxicity, likely due to off-target effects, possibly including
the inhibition of CCR1. However, the structure of the US28 protein has recently been
solved (46) and could aid the development of more-speciﬁc small-molecule inverse
agonists of US28.
Taken together, our observations point to a crucial role for viral US28 in the
establishment of HCMV latency in monocytes which is mediated by differentiation-
dependent US28 signaling and indicate that inhibition of US28, resulting in the
induction of IE expression in normally latently infected cells, could aid in novel
immunotherapeutic strategies to target and clear the HCMV latent reservoir in certain
clinical settings.
MATERIALS AND METHODS
Cell culture and virus infection. Viral isolates of the Titan wild type (Titan-WT) and the equivalent
isolate with a deletion in the US28 gene (Titan-ΔUS28) which have a UL32-GFP tag have been described
previously (68), as has an isolate of TB40/E, a wild-type clinical isolate of HCMV carrying an SV40-GFP
expression cassette tag (termed SV40-GFP-TB40E) which allows the detection of latently infected cells
(81), as well as an isolate of TB40/E with an IE2-YFP tag (termed RV1164) (40). Primary CD14monocytes
were isolated from apheresis cones (NHS Blood and Transfusion Service, United Kingdom) as described
previously (90) and cultured in X-vivo15 (Lonza) at 37°C in 5% CO2. Cells were infected with all HCMV viral
isolates at a predicted multiplicity of infection (MOI) of 5 (based on infection of RPE-1 cells), leading to
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10% latently infected cells as determined by GFP expression upon infection with SV40-GFP-TB40E.
Monocytes were activated to differentiate into immature dendritic cells by granulocyte-macrophage
colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) (PeproTech) stimulation at 1,000 U/ml for 5
days. Mature dendritic cells were produced by stimulation for 2 further days with lipopolysaccharide at
500 ng/ml.
THP-1 cells were infected for 3 days with Titan-WT, Titan-ΔUS28, or SV40-GFP-TB40E at a predicted
MOI of 5 (based on infection of RPE-1 cells) and were differentiated using 50 ng/l phorbol myristate
acetate (PMA) as previously described (91). To quantify reactivation/virus release, cells were cocultured
with 3  103 ﬁbroblast cells per cm2 of growth area in a 50:50 mixture of Dulbecco’s modiﬁed Eagle’s
medium 10 (DMEM-10) and RPMI-20 or X-vivo15 (Lonza).
RT-qPCR. Monocytes were infected with Titan-WT or Titan-ΔUS28. After 3 h of incubation, cultures
were washed with citrate to remove cell-associated virus. Samples for each condition were then
harvested immediately into TRIzol (Life Technologies, Inc.) to act as control wells for input mRNA from
incoming virions. Other cultures were incubated for the duration of time indicated for each experiment
(between 1 and 7 days) before also being harvested in TRIzol, and mRNA was then isolated using a
miRNeasy minikit (Qiagen), following the manufacturer’s instructions. UL138, IE, and UL99 were quan-
tiﬁed using one-step reverse transcription-qPCR (RT-qPCR) and a QuantiTect virus kit (Qiagen) as
previously described (41). Values were calculated using the threshold cycle (ΔΔCT) method and expressed
as relative changes between the input control and the relevant time point. Samples were normalized to
GAPDH (glyceraldehyde-3-phosphate dehydrogenase), as described previously (41).
IF staining and microscopy. Cells were ﬁxed and stained as described previously (92). In brief,
following ﬁxation in paraformaldehyde and permeabilization in 70% ethanol, cells were washed in
phosphate-buffered saline (PBS) and stained with mouse anti-IE (Argene 11-003) diluted at 1 in 1,000 in
PBS containing 10% goat serum. This was followed by detection with goat anti-mouse antibody (Alexa
Fluor 594). Where indicated, goat anti-GFP (ﬂuorescein isothiocyanate [FITC] conjugated; Abcam, Inc.)
and Hoechst 33258 nuclear stain were added simultaneously.
Virus release assays. Media was harvested from infected monocyte cultures and titrated onto
human foreskin ﬁbroblasts (HFFs). Following 3 h of incubation with rocking at room temperature, the
cultures were then washed, media were replaced, and the cultures were incubated for a further 24 h at
37°C in 5% CO2. Fibroblasts were then stained for immediate early antigen, using the protocol described
above, and the virus titer was calculated as the number of infected cells per microliter of monocyte
supernatant media added to the ﬁbroblast culture.
Lentiviral transduction of US28 expression and conﬁrmation of expression by Western blot-
ting. Lentiviral US28 expression constructs where US28 expression is driven by a spleen focus-forming
virus (SFFV) promoter with an N-terminal hemagglutinin tag (HA) were kindly provided by Daniel
Streblow (Oregan Health and Science University) and transduced into THP-1 cells, followed by conﬁr-
mation by Western blotting, as previously described (73).
Detection of phosphoproteins by immunoblotting. THP-1 cells, transduced to express various
constructs of HA-US28, were lysed in radioimmunoprecipitation assay (RIPA) buffer, and nuclei and cell
debris were removed by centrifugation at 13,000  g for 10 min at 4°C. Proteins were separated on 10%
SDS-polyacrylamide gels and transferred to nitrocellulose membranes (Axygen; Corning). Incubations
with primary and secondary antibodies were performed using 5% skimmed milk for 1 h each at room
temperature. Proteins were detected using the following antibodies: anti-p42/p44 or phosphor-anti-p42/
p44 antibodies or anti-MSK1 or anti-phosphor-MSK1 antibodies (serine 360) (all 1:1,000; Cell Signalling
Technology, Danvers, MA) or anti-CREB or phosphor-CREB antibodies (S360) (both Merck). The secondary
antibody used was chicken anti-rabbit horseradish peroxidase (Santa Cruz Biotech). Blots were developed
with the use of enhanced chemiluminescence (GE Healthcare) and visualized with autoradiography ﬁlm.
To detect cellular localization of NF-kB, cells were fractionated using REAP (rapid, efﬁcient, and
practical) (93) and proteins detected using the following antibodies: anti-NF-B (Abcam, Inc.), anti-p84
(Thermo), and anti-GAPDH (Millipore). Secondary antibodies used were chicken anti-rabbit and bovine
anti-mouse horseradish peroxidase (both Santa Cruz Biotech).
MIEP activation/repression assays using THP-1 cells. THP-1 cells expressing an MIEP-eGFP con-
struct have been previously described (76). These cells were transfected by nucleofection with various
US28 constructs, using Amaxa Cell Line Nucleofector Kit R (Lonza); MIEP-driven eGFP expression was
detected and measured using a BD Accuri C6 ﬂow cytometer, where dead cells were excluded from
analysis by staining with Zombie Red ﬁxable viability dye (BioLegend); and mean ﬂuorescence intensities
for eGFP expression were analyzed within the same experiment using FlowJo software (Tree Star Inc.).
Phosphokinase arrays. For phosphokinase antibody arrays, THP-1 cells were transduced with
lentiviral US28 expression vectors, as described previously (73). Cells were harvested and lysed following
the manufacturer’s protocol (Proteome Proﬁler human phospho-kinase array kit; R&D Systems), and spot
intensity was analyzed using ImageJ software.
IE-speciﬁc T cell and PBMC killing assays. CD14 monocytes were plated at 1  105 cells per well
of a 96-well plate and infected with Titan-WT, Titan-ΔUS28, or SV40-GFP-TB40E. Three days postinfection,
the monocytes were then cocultured with HLA-matched (HLA-A2) immediate-early-speciﬁc CD8 T cells
(94) at an effector-to-target cell (E:T) ratio of 5:1 or with donor PBMCs at an E:T ratio of 1:3. VUF2274 was
added to the relevant wells at a concentration of 6  107 M. In order to measure the killing of latently
infected monocytes, the numbers of HCMV-infected, GFP-expressing, or UL32-GFP-expressing monocytes
were enumerated, by ﬂuorescence microscopy, over several days as indicated. Media from these cultures
were collected to determine the titer of any virus that was produced by Titan-ΔUS28-infected monocytes
before they were differentiated to dendritic cells by cytokine treatment. To quantify virus reactivation
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events, these monocyte-derived dendritic cells were cocultured with indicator ﬁbroblasts for 2 weeks and
reactivation events enumerated by IF staining for IE and by counting IE-positive foci.
Flow cytometry. Experimentally infected monocytes were coincubated with CD8 T cells from the
same, seropositive donor overnight in the presence of CD107a Alexa Fluor 647, 5 g/ml brefeldin A, and
2 M monensin (all from BioLegend) at 37°C. CD8 T cells were harvested and washed and then stained
with a combination of surface antibodies (CD3 brilliant violet 650, CD14 brilliant violet 510, and CD19
brilliant violet 510; BioLegend) and LIVE/DEAD Fixable Aqua Dead cell stain (Invitrogen) at 4°C. Cells were
ﬁxed and permeabilized using FIX & PERM (ADG, Kaumberg, Austria) and stained intracellularly with
antibodies (CD69 Paciﬁc Blue, 4-1BB phycoerythrin [PE]-Cy5, CD8 brilliant violet 570, and granzyme A
FITC [BioLegend]; granzyme B FITC [Miltenyi Biotec, Inc.]; granzyme K FITC [Santa Cruz Biotechnology, TX,
USA]; TNF- brilliant ultraviolet 395 and IFN- brilliant violet 786). Responding CD8 T cell populations
were identiﬁed by the expression of CD69 and 4-1BB at levels above the background, and expression
levels of CD107a, TNF-, and IFN- were then measured. In all cases, cell doublets, monocytes, B cells,
and dead cells were eliminated from the analyzed populations.
To analyze differentiation markers, monocytes were labeled with anti-CD14 and anti-CD83 antibodies
(BioLegend) (both allophycocyanin [APC] conjugated).
Chromatin immunoprecipitation. Chromatin immunoprecipitation of the MIEP was performed
using a Sigma Imprint ChIP kit and antibodies against S10P and HP1 (HP1 antibody [FL-191; catalog no.
sc-28735] and anti-ser-10-H3 [phospho-histone H3 {Ser10} antibody {9H12L10}]; ABﬁnity Rabbit Mono-
clonal). The MIEP was quantitated against a standard curve of viral DNA, analyzed by qPCR, and then
plotted as a percentage of input DNA, with each sample run in triplicate. The primers and probe
used were as follows: forward primer, CCAAGTCTCCACCCCATTGAC; reverse primer, GACATTTTGGA
AAGTCCCGTTG; probe, 6-carboxyﬂuorescein (FAM)-TGGGAGTTTGTTTTGGCACCAAA-6-carboxytetra-
methylrhodamine (TAMRA).
Ethics statement. All human samples were obtained under ethical approval by and after approval
of protocols from the Cambridgeshire 2 Research Ethics Committee (REC reference 97/092) conducted in
accordance with the Declaration of Helsinki. Informed written consent was obtained from all of the
volunteers included in this study before providing blood samples, and all experiments were carried out
in accordance with the approved guidelines.
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